| Date:25.10.2021      |  |
|----------------------|--|
| Your Name:           | Hui Qi   |
| Manuscript Title:    | Blood digital polymerase chain reaction as a potential method to detect human epidermal growth |
| factor receptor 2 an | nplification in non-small cell lung cancer   |
| Manuscript number    | r (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, | XNone  |   |
|   | provision of study materials,                          |  |   |
|   | medical writing, article                               |  |   |
|   | processing charges, etc.)                              |  |   |
|   | No time limit for this item.                           |  |   |
|   |  |  |   |
|   |  | <b>—</b> •   |   |
|   | -  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                               | XNone  |   |
|   | any entity (if not indicated                           |  |   |
|   | in item #1 above).                                     |  |   |
| 3 | Royalties or licenses                                  | XNone  |   |
|   |  |  |   |
|   |  |  |   |
| 4 | Consulting fees  | XNone  |   |
|   |  |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,                 | XNone |  |
|----|---|-------|--|
|    | manuscript writing or<br>educational events   |       |  |
| 6  | Payment for expert testimony  | XNone |  |
| 7  | Support for attending meetings and/or travel  | XNone |  |
|    |   |       |  |
|    |   |       |  |
| 8  | Patents planned, issued or<br>pending   | XNone |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                   | XNone |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy         | XNone |  |
| 11 | group, paid or unpaid<br>Stock or stock options   | XNone |  |
|    |   |       |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services | XNone |  |
| 13 | Other financial or non-<br>financial interests  | XNone |  |
|    |   |       |  |

None.

Please place an "X" next to the following statement to indicate your agreement:

| Date:25.10.            | 2021  |
|------------------------|---|
| Your Name:             | Anwen Xiong   |
| <b>Manuscript Titl</b> | e: Blood digital polymerase chain reaction as a potential method to detect human epidermal growth |
| factor receptor        | 2 amplification in non-small cell lung cancer   |
| Manuscript nur         | mber (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,                 | XNone |  |
|----|---|-------|--|
|    | manuscript writing or<br>educational events   |       |  |
| 6  | Payment for expert testimony  | XNone |  |
| 7  | Support for attending meetings and/or travel  | XNone |  |
|    |   |       |  |
|    |   |       |  |
| 8  | Patents planned, issued or<br>pending   | XNone |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                   | XNone |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy         | XNone |  |
| 11 | group, paid or unpaid<br>Stock or stock options   | XNone |  |
|    |   |       |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services | XNone |  |
| 13 | Other financial or non-<br>financial interests  | XNone |  |
|    |   |       |  |

None.

Please place an "X" next to the following statement to indicate your agreement:

| Date:2      | 5 <b>.10.202</b> 1 |  |
|-------------|--------------------|--|
| Your Nam    | e:                 | Lei Jiang  |
| Manuscrip   | ot Title:          | Blood digital polymerase chain reaction as a potential method to detect human epidermal growth |
| factor rece | eptor 2 ar         | nplification in non-small cell lung cancer   |
| Manuscrip   | ot numbe           | ' (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | XNone   |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | XNone   |   |
| 3 | Royalties or licenses  | XNone   |   |
| 4 | Consulting fees  | XNone   |   |

| 5  | Payment or honoraria for                        | X None |  |
|----|---|--------|--|
| 5  | lectures, presentations,                        |        |  |
|    | speakers bureaus,                               |        |  |
|    | manuscript writing or                           |        |  |
|    | educational events                              |        |  |
| 6  | Payment for expert                              | XNone  |  |
|    | testimony                                       |        |  |
|    |   |        |  |
| 7  | Support for attending<br>meetings and/or travel | XNone  |  |
|    |   |        |  |
|    |   |        |  |
| 8  | Patents planned, issued or                      | XNone  |  |
|    | pending   |        |  |
|    |   |        |  |
| 9  | Participation on a Data                         | XNone  |  |
|    | Safety Monitoring Board or                      |        |  |
|    | Advisory Board                                  |        |  |
| 10 | Leadership or fiduciary role                    | XNone  |  |
|    | in other board, society,                        |        |  |
|    | committee or advocacy group, paid or unpaid     |        |  |
| 11 | Stock or stock options                          | X None |  |
|    |   |        |  |
|    |   |        |  |
| 12 | Receipt of equipment,                           | XNone  |  |
|    | materials, drugs, medical                       |        |  |
|    | writing, gifts or other                         |        |  |
|    | services  |        |  |
| 13 | Other financial or non-                         | XNone  |  |
|    | financial interests                             |        |  |
|    |   |        |  |

None.

# Please place an "X" next to the following statement to indicate your agreement:

| Date:2           | Date:25.10.2021 |  |  |  |  |
|------------------|-----------------|--|--|--|--|
| Your Name        | e: I            | Hardy Van  |  |  |  |
| Manuscrip        | t Title:        | "Blood droplet digital polymerase chain reaction as a potential method to detect human |  |  |  |
| <u>epidermal</u> | growth fa       | ctor receptor 2 amplification in non-small cell lung cancer"                           |  |  |  |
| Manuscrip        | ot number       | (if known):  |  |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| 5  | Payment or honoraria for lectures, presentations, speakers bureaus,  | XNone                  |  |
|----|--|------------------------|--|
|    | manuscript writing or<br>educational events  |                        |  |
| 6  | Payment for expert testimony   | XNone                  |  |
| 7  | Support for attending meetings and/or travel   | XNone                  |  |
|    |  |                        |  |
| 8  | Patents planned, issued or<br>pending  | XNone                  |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | XNone                  |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | XNone                  |  |
| 11 | Stock or stock options   | XNone                  |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | XNone                  |  |
| 13 | Other financial or non-<br>financial interests   | Alphamab Oncology Ltd. |  |

The author is from Alphamab Oncology Ltd.

Please place an "X" next to the following statement to indicate your agreement:

| Date:25.10.2021   |  |  |  |  |
|---|--|--|--|--|
| /our Name: June Xu  |  |  |  |  |
| Manuscript Title: <u>"Blood droplet digital polymerase chain reaction as a potential method to detect human</u> |  |  |  |  |
| epidermal growth factor receptor 2 amplification in non-small cell lung cancer"                                 |  |  |  |  |
| Manuscript number (if known):   |  |  |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | XNone  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | XNone  |   |
| 3 | Royalties or licenses  | XNone  |   |
| 4 | Consulting fees  | XNone  |   |

| 5  | Payment or honoraria for lectures, presentations,  | XNone                 |  |
|----|--|-----------------------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events   |                       |  |
| 6  | Payment for expert testimony   | XNone                 |  |
| 7  | Support for attending meetings and/or travel   | XNone                 |  |
|    |  |                       |  |
| 8  | Patents planned, issued or<br>pending  | XNone                 |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                    | XNone                 |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid | XNone                 |  |
| 11 | Stock or stock options   | XNone                 |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                  | XNone                 |  |
| 13 | Other financial or non-<br>financial interests   | Alphamab Oncology Ltd |  |

The author is from Alphamab Oncology Ltd.

Please place an "X" next to the following statement to indicate your agreement:

| ate:25.10.2021   |  |  |  |  |
|--|--|--|--|--|
| our Name: Jing Wu  |  |  |  |  |
| anuscript Title: <u>"Blood droplet digital polymerase chain reaction as a potential method to detect human</u> |  |  |  |  |
| epidermal growth factor receptor 2 amplification in non-small cell lung cancer"                                |  |  |  |  |
| Manuscript number (if known):  |  |  |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| 5   | Payment or honoraria for                             | XNone                     |  |
|-----|--|---------------------------|--|
|     | lectures, presentations,                             |                           |  |
|     | speakers bureaus,                                    |                           |  |
|     | manuscript writing or                                |                           |  |
|     | educational events                                   |                           |  |
| 6   | Payment for expert                                   | XNone                     |  |
|     | testimony  |                           |  |
|     |  |                           |  |
| 7   | Support for attending<br>meetings and/or travel      | XNone                     |  |
|     |  |                           |  |
|     |  |                           |  |
| 8   | Patents planned, issued or                           | XNone                     |  |
|     | pending  |                           |  |
|     |  |                           |  |
| 9   | Participation on a Data                              | XNone                     |  |
|     | Safety Monitoring Board or                           |                           |  |
|     | Advisory Board                                       |                           |  |
| 10  | Leadership or fiduciary role                         | XNone                     |  |
|     | in other board, society,                             |                           |  |
|     | committee or advocacy                                |                           |  |
|     | group, paid or unpaid                                |                           |  |
| 11  | Stock or stock options                               | XNone                     |  |
|     |  |                           |  |
| 4.2 |  | × N                       |  |
| 12  | Receipt of equipment,                                | XNone                     |  |
|     | materials, drugs, medical<br>writing, gifts or other |                           |  |
|     | services   |                           |  |
| 13  | Other financial or non-                              | Genetron Health (Beijing) |  |
|     | financial interests                                  | Co. Ltd.                  |  |
|     |  |                           |  |
|     |  |                           |  |

The author is from Genetron Health (Beijing) Co. Ltd.

Please place an "X" next to the following statement to indicate your agreement:

| Date:25.10.2021   |  |  |  |  |
|---|--|--|--|--|
| Your Name: Qiaosong Zheng   |  |  |  |  |
| Nanuscript Title:   |  |  |  |  |
| epidermal growth factor receptor 2 amplification in non-small cell lung cancer" |  |  |  |  |
| Manuscript number (if known):   |  |  |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present                              | XNone  |   |
|   | manuscript (e.g., funding, provision of study materials, |  |   |
|   | medical writing, article                                 |  |   |
|   | processing charges, etc.)                                |  |   |
|   | No time limit for this item.                             |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                                 | XNone  |   |
|   | any entity (if not indicated                             |  |   |
|   | in item #1 above).                                       |  |   |
| 3 | Royalties or licenses                                    | XNone  |   |
|   |  |  |   |
|   |  |  |   |
| 4 | Consulting fees  | XNone  |   |
|   |  |  |   |

| 5  | Payment or honoraria for                        | XNone                     |  |
|----|---|---------------------------|--|
|    | lectures, presentations,                        |                           |  |
|    | speakers bureaus,                               |                           |  |
|    | manuscript writing or                           |                           |  |
|    | educational events                              |                           |  |
| 6  | Payment for expert                              | XNone                     |  |
| ļ  | testimony                                       |                           |  |
|    |   |                           |  |
| 7  | Support for attending<br>meetings and/or travel | XNone                     |  |
|    |   |                           |  |
|    |   |                           |  |
| 8  | Patents planned, issued or                      | XNone                     |  |
|    | pending   |                           |  |
|    |   |                           |  |
| 9  | Participation on a Data                         | XNone                     |  |
|    | Safety Monitoring Board or                      |                           |  |
|    | Advisory Board                                  |                           |  |
| 10 | Leadership or fiduciary role                    | XNone                     |  |
| ļ  | in other board, society,                        |                           |  |
|    | committee or advocacy<br>group, paid or unpaid  |                           |  |
| 11 | Stock or stock options                          | XNone                     |  |
|    |   |                           |  |
|    |   |                           |  |
| 12 | Receipt of equipment,                           | XNone                     |  |
|    | materials, drugs, medical                       |                           |  |
|    | writing, gifts or other services                |                           |  |
| 13 | Other financial or non-                         | Genetron Health (Beijing) |  |
|    | financial interests                             | Co. Ltd.                  |  |
|    |   |                           |  |
|    |   |                           |  |

The author is from Genetron Health (Beijing) Co. Ltd.

Please place an "X" next to the following statement to indicate your agreement:

| Date: 12 October 2021   |  |  |  |  |
|---|--|--|--|--|
| Your Name: Fabrizio Minervini   |  |  |  |  |
| Manuscript Title: <u>Blood digital polymerase chain reaction as a potential method to detect human epidermal growth</u> |  |  |  |  |
| factor receptor 2 amplification in non-small cell lung cancer   |  |  |  |  |
| Manuscript number (if known):   |  |  |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | XNone |  |
|----|--|-------|--|
| 6  | Payment for expert testimony   | XNone |  |
| 7  | Support for attending meetings and/or travel   | XNone |  |
| 8  | Patents planned, issued or pending   | XNone |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | XNone |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | XNone |  |
| 11 | Stock or stock options   | XNone |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | XNone |  |
| 13 | Other financial or non-<br>financial interests   | XNone |  |

None.

Please place an "X" next to the following statement to indicate your agreement:

| Date:18.10.2021   |
|---|
| Your Name:Dinora Polanco Alonso   |
| Manuscript Title:_ Blood digital polymerase chain reaction as a potential method to detect human epidermal growth |
| factor receptor 2 amplification in non-small cell lung cancer   |
| Manuscript number (if known):   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | XNone   |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | XNone   |   |
| 3 | Royalties or licenses  | XNone   |   |
| 4 | Consulting fees  | XNone   |   |

| 5        | Payment or honoraria for                                 | XNone   |  |
|----------|--|---------|--|
|          | lectures, presentations,                                 |         |  |
|          | speakers bureaus,  |         |  |
|          | manuscript writing or                                    |         |  |
| 6        | educational events                                       |         |  |
| 6        | Payment for expert                                       | XNone   |  |
| ļ        | testimony  |         |  |
| 7        | Support for attending                                    | X None  |  |
| <i>'</i> | meetings and/or travel                                   |         |  |
|          |  |         |  |
|          |  |         |  |
|          |  |         |  |
| 8        | Patents planned, issued or                               | XNone   |  |
|          | pending  |         |  |
|          |  |         |  |
| 9        | Participation on a Data                                  | XNone   |  |
| l        | Safety Monitoring Board or                               |         |  |
| 10       | Advisory Board   | . Maria |  |
| 10       | Leadership or fiduciary role<br>in other board, society, | XNone   |  |
|          | committee or advocacy                                    |         |  |
|          | group, paid or unpaid                                    |         |  |
| 11       | Stock or stock options                                   | X None  |  |
| l        |  |         |  |
|          |  |         |  |
| 12       | Receipt of equipment,                                    | XNone   |  |
| ļ        | materials, drugs, medical                                |         |  |
|          | writing, gifts or other                                  |         |  |
| 42       | services   |         |  |
| 13       | Other financial or non-<br>financial interests           | XNone   |  |
|          | Tinancial Interests                                      |         |  |
|          |  |         |  |

None.

Please place an "X" next to the following statement to indicate your agreement:

| Date:25.10.2021   |             |
|---|-------------|
| Your Name: Yifu Yang  |             |
| Manuscript Title: Blood digital polymerase chain reaction as a potential method to detect human epidermal gro | <u>owth</u> |
| factor receptor 2 amplification in non-small cell lung cancer   |             |
| Manuscript number (if known):   |             |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | XNone  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | XNone  |   |
| 3 | Royalties or licenses  | XNone  |   |
| 4 | Consulting fees  | XNone  |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events<br>Payment for expert<br>testimony | XNone |  |
|----|---|-------|--|
| 7  | Support for attending meetings and/or travel  | XNone |  |
| 8  | Patents planned, issued or<br>pending   | XNone |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board   | XNone |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid  | XNone |  |
| 11 | Stock or stock options  | XNone |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services   | XNone |  |
| 13 | Other financial or non-<br>financial interests  | XNone |  |

None.

Please place an "X" next to the following statement to indicate your agreement:

| Date:25.10      | .2021  |
|-----------------|--|
| Your Name:      | Liang Wu   |
| Manuscript Tit  | le: Blood digital polymerase chain reaction as a potential method to detect human epidermal growth |
| factor receptor | r 2 amplification in non-small cell lung cancer  |
| Manuscript nu   | mber (if known):   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | XNone   |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | XNone   |   |
| 3 | Royalties or licenses  | XNone   |   |
| 4 | Consulting fees  | XNone   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | XNone |  |
|----|--|-------|--|
| 6  | Payment for expert testimony   | XNone |  |
| 7  | Support for attending meetings and/or travel   | XNone |  |
| 8  | Patents planned, issued or pending   | XNone |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | XNone |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | XNone |  |
| 11 | Stock or stock options   | XNone |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | XNone |  |
| 13 | Other financial or non-<br>financial interests   | XNone |  |

None.

Please place an "X" next to the following statement to indicate your agreement: